https://www.selleckchem.com/pr....oducts/miransertib.h
Tegaserod is a 5-HT receptor agonist approved for irritable bowel syndrome with constipation in women 65 years of age without a history of cardiovascular ischemic events. Safety data are presented from 2 external adjudications from the 2018 Gastrointestinal Drugs Advisory Committee meeting supporting tegaserod's reintroduction after its voluntary 2007 withdrawal. Withdrawal was based on an internal adjudication using pooled placebo-controlled tegaserod data to identify potential cardiovascular ischemic signals. An independent co
Curtir
Comentario
Compartilhar
